Toward Translation of Nanotechnology Cancer Interventions (TTNCIs)

TTNCI’s enable the translation of nanotechnology-based cancer interventions relying on next-generation nanoparticle formulations and/or nano-devices. The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. These awards are designed to mature experimental nanomedicines relying on "next-generation" nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.

• Alexander Kabanov – UNIVERSITY OF NORTH CAROLINA CHAPEL HILL – Toward Translation of Nanaoformulated Paclitaxel-Platinum Combination 
• Cesar Castro/Hakho Lee – MASSACHUSETTS GENERAL HOSPITAL – High Throughput Nanoplasmonic Exosome Testing (NEXT) of Immunotherapies in Bladder Cancer
• Chun Li – UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER –Pre-IND Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy
• Glen Kwon – UNIVERSITY OF WISCONSIN-MADISON – Oligo(lactic acid)n-Prodrug Nanomedicines for Combination Therapy
• Matthias Stephan – FRED HUTCHINSON CANCER RESEARCH CENTER – Developing Macrophage Reprogramming mRNA Nanocarriers for Initial Clinical Testing
• Hu Yan/Kristoffer Valerie – MISSOURI UNIVERSITY OF SCIENCE & TECHNOLOGY– PEAMOtecan, A Novel Chronotheranostic Polymeric Drug for Brain Cancer with Potential Multi-Prong Drug Delivery Capability
• Jin Xie/Zibo Li/William Kim – UNIVERSITY OF GEORGIA – Development of A Novel Biodegradable Inorganic Nanoparticle Therapeutic for Cancer
• John Tanner Wilson – VANDERBILT UNIVERSITY – Toward Translation of an Immunotherapeutic Nanomedicine for Neuroblastoma 
• Raghuramann Kannan – UNIVERSITY OF MISSOURI-COLUMBIA – Towards Translation of MU-CN29: New Therapeutic Nanoparticle for DrugResistant NSCLC
• Shan Wang – STANFORD UNIVERSITY – Rapid and Affordable Magneto-Nanosensors for ctDNA-Guided Lung Cancer Management
• Yoon Yeo/Stephen Kron – PURDUE UNIVERSITY –Systemic Delivery of siRNA by Nanosac for Checkpoint Blockade Immunotherapy of Head and Neck Squamous Cell Cancer